Status:
COMPLETED
18FDG- PET/CT Contribution to the Assessment of Lesion Severity in Cystic Fibrosis (CF)
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
10+ years
Phase:
NA
Brief Summary
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF trans-membrane conductance regulator (CFTR) protein. CF is the most common inherited disease of Caucasians, with a...
Detailed Description
Cystic fibrosis patients with active lung disease will undergo a high resolution PET-CT.PET/CT scans (GE ST Discovery PET/CT scanner) will be performed 60 to 90 minutes after injection of 5 MBq/kg of ...
Eligibility Criteria
Inclusion
- CF patients with active lesions in their lungs -
Exclusion
- pregnancy,
- \-
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00363402
Start Date
August 1 2006
End Date
December 1 2007
Last Update
May 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 24035